Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SLS-008
- Development stage
- Preclinical
- Lead developer
- Seelos Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SLS-008 is a small molecule, orally bioavailable antagonist of the prostaglandin D2 (PGD2) receptor, specifically targeting the chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2). It is developed for the treatment of atopic dermatitis, pediatric esophagitis, and asthma. Initially developed by Ligand Pharmaceuticals, it is currently in the preclinical phase of development.
- Other names
- SLS008SLS-008SLS 008
02
Targets
PTGDR2 (Prostaglandin D2 receptor 2)PTGDR (Prostanoid DP1 receptor)
Beyond the preview
Go deeper on SLS-008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLS-008.